Breaking Finance News

A report released today by Chardan Capital about Biocept (NASDAQ:BIOC) drops the target price to $1.50

In a statement issued on Tuesday November 14, 2017 Chardan Capital dropped the price target of Biocept (NASDAQ:BIOC) from $2.50 to $1.50 indicating a possible upside of 0.70%.

Showing a price of $0.88, Biocept (NASDAQ:BIOC) traded 0.00% even on the day. With the last close down -29.71% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.02% over the date range. Biocept has recorded a 50-day average of $1.21 and a two hundred day average of $1.38. Trade Volume was up over the average, with 339,362 shares of BIOC changing hands over the typical 295,600

See Chart Below


With a total market value of $0, Biocept has with a one year low of $0.74 and a one year high of $3.39 .

About Biocept (NASDAQ:BIOC)

Biocept, Inc. is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company's Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample. The ctDNA technology enables mutation detection and is applicable to nucleic acid from CTCs or other sample types, such as blood plasma. The Company commercializes its Target-Selector assays for a range of solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), gastric cancer, colorectal cancer, prostate cancer and melanoma.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.